Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

##STR00001##

Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.

Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.

Provided is a thiobenzopyran-based compound of Formula I and its pharmaceutically acceptable salt, and its use in the preparation of drugs for the treatment of rheumatoid arthritis, wherein X is selected from oxygen, sulfur, —SO—, and —SO.sub.2—; Y is a sulfur atom and Z is H, Na, or K. Through preliminary tests of anti-inflammatory activity, compounds of formula I have anti-rheumatoid arthritis effects.

##STR00001##

Provided is a thiobenzopyran-based compound of Formula I and its pharmaceutically acceptable salt, and its use in the preparation of drugs for the treatment of rheumatoid arthritis, wherein X is selected from oxygen, sulfur, —SO—, and —SO.sub.2—; Y is a sulfur atom and Z is H, Na, or K. Through preliminary tests of anti-inflammatory activity, compounds of formula I have anti-rheumatoid arthritis effects.

##STR00001##

The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.

The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.

A resist composition comprising a sulfonium salt of carboxylic acid having a coumarin or thiocoumarin structure as the quencher is provided. The resist composition offers a high sensitivity, reduced LWR and improved CDU independent of whether it is of positive or negative tone.

A resist composition comprising a sulfonium salt of carboxylic acid having a coumarin or thiocoumarin structure as the quencher is provided. The resist composition offers a high sensitivity, reduced LWR and improved CDU independent of whether it is of positive or negative tone.

The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by RORγ.